The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 28, 2015
Filed:
May. 24, 2010
Young-hoon Ji, Seoul, KR;
Dong-hee Kim, Gimhae-si, KR;
Jae-seon Kang, Busan, KR;
Chun-gyu Kim, Gimhae-si, KR;
Sung-uk Chung, Seoul, KR;
Sung-woo Hwang, Busan, KR;
Kyung-ran Kang, Busan, KR;
Young-Hoon Ji, Seoul, KR;
Dong-Hee Kim, Gimhae-si, KR;
Jae-Seon Kang, Busan, KR;
Chun-Gyu Kim, Gimhae-si, KR;
Sung-Uk Chung, Seoul, KR;
Sung-Woo Hwang, Busan, KR;
Kyung-Ran Kang, Busan, KR;
DAEWOO PHARMACEUTICAL IND. CO., LTD., Busan, KR;
Abstract
The present invention relates to an anti-inflammatory use of macrolactin compounds such as macrolactin A, 7-O-malonyl macrolactin A and 7-O-succinyl macrolactin A, which are produced from a novelstrain ofKJS-2 (KCCM10769P). The macrolactin compounds provided by the present invention were confirmed to greatly suppress the expression and formation of inducible nitric oxide synthetase (iNOS) and cyclooxygenase-2 (COX-2) which are proteins related to the formation of inflammatory mediators, and to accordingly inhibit the formation of nitric oxide (NO) and of prostaglandin E2 (PGE2) which are the metabolites of the proteins. In addition, the macrolactin compounds provided by the present invention were confirmed to have excellent effects in inhibiting the formation of tumor necrosis factor-alpha (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6) and granulocyte macrophage colony-stimulating factor (GM-CSF), which are pro-inflammatory cytokines. Therefore, the macrolactin compounds produced by theKJS-2 strain according to the present invention can provide excellent anti-inflammatory agents.